Safety of high dose trivalent inactivated influenza vaccine in pediatric patients with acute lymphoblastic leukemia

Pediatric Blood and Cancer

Volumn 61, Issue 5, 2014, Pages 815-820

  Mcmanus, Meghann ^a   Frangoul, Haydar ^b   Mccullers, Jonathan A ^c,d   Wang, Li ^b   O'Shea, Alice ^b   Halasa, Natasha ^b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^d UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Children; Influenza; Leukemia; Trivalent inactivated influenza vaccine

Indexed keywords

ANTINEOPLASTIC AGENT; HIGHDOSE FLUZONE; INFLUENZA VACCINE; UNCLASSIFIED DRUG; VIRUS ANTIGEN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ANTIBODY TITER; ARTICLE; CANCER CHEMOTHERAPY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HEMAGGLUTINATION INHIBITION TEST; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA A (H1N1); INFLUENZA VACCINATION; INFLUENZA VIRUS; INFLUENZA VIRUS A H1N1; INJECTION SITE PAIN; INJECTION SITE REACTION; LABORATORY TEST; MAINTENANCE THERAPY; MALE; PATIENT MONITORING; PEDIATRICS; PHASE 1 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SEASONAL INFLUENZA; SYMPTOM; TREATMENT DURATION; VIRUS STRAIN;

CHILDREN; INFLUENZA; LEUKEMIA; TRIVALENT INACTIVATED INFLUENZA VACCINE;

ADOLESCENT; ANTIBODIES, VIRAL; CHILD; CHILD, PRESCHOOL; DOUBLE-BLIND METHOD; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; FOLLOW-UP STUDIES; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFLUENZA A VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; INJECTIONS, INTRAMUSCULAR; MALE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; RISK FACTORS; VACCINATION; VACCINES, INACTIVATED;

EID: 84895739693     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24863     Document Type: Article

References (33)

1. Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003; 289:179-186.
2. Harper SA, Fukuda K, Uyeki TM, et al. Prevention and control of influenza: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2004; 53:1-40.
3. Barker WH. Excess pneumonia and influenza associated hospitalization during influenza epidemics in the United States, 1970-78. Am J Public Health 1986; 76:761-765.
4. Tasian SK, Park JR, Martin ET, et al. Influenza-associated morbidity in children with cancer. Pediatr Blood Cancer 2008; 50:983-987.
5. Goossen GM, Kremer LC, van de Wetering MD. Influenza vaccination in children being treated with chemotherapy for cancer. Cochrane Database Syst Rev 2009; CD006484.
6. Kempe A, Hall CB, MacDonald NE, et al. Influenza in children with cancer. J Pediatr 1989; 115:33-39.
7. Feldman S, Webster RG, Sugg M. Influenza in children and young adults with cancer: 20 cases. Cancer 1977; 39:350-353.
8. Potter MN, Foot AB, Oakhill A. Influenza A and the virus associated haemophagocytic syndrome: Cluster of three cases in children with acute leukaemia. J Clin Pathol 1991; 44:297-299.
9. Cost C, Brock E, Adams-Huet B, et al. 2009 pandemic influenza a (H1N1) virus infection in pediatric oncology and hematopoietic stem cell transplantation patients. Pediatr Blood Cancer.
10. Klimov AI, Rocha E, Hayden FG, et al. Prolonged shedding of amantadine-resistant influenzae A viruses by immunodeficient patients: Detection by polymerase chain reaction-restriction analysis. J Infect Dis 1995; 172:1352-1355.
11. Weinstock DM, Gubareva LV, Zuccotti G. Prolonged shedding of multidrug-resistant influenza A virus in an immunocompromised patient. N Engl J Med 2003; 348:867-868.
12. Baz M, Abed Y, McDonald J, et al. Characterization of multidrug-resistant influenza A/H3N2 viruses shed during 1 year by an immunocompromised child. Clin Infect Dis 2006; 43:1555-1561.
13. Fiore AE, Uyeki TM, Broder K, et al. Prevention and control of influenza with vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2010; 59:1-62.
14. Porter CC, Edwards KM, Zhu Y, et al. Immune responses to influenza immunization in children receiving maintenance chemotherapy for acute lymphoblastic leukemia. Pediatr Blood Cancer 2004; 42:36-40.
15. Matsuzaki A, Suminoe A, Koga Y, et al. Immune response after influenza vaccination in children with cancer. Pediatr Blood Cancer 2005; 45:831-837.
16. Brydak LB, Rokicka-Milewska R, Jackowska T, et al. Kinetics of humoral response in children with acute lymphoblastic leukemia immunized with influenza vaccine in 1993 in Poland. Leuk Lymphoma 1997; 26:163-169.
17. Brydak LB, Rokicka-Milewska R, Machala M, et al. Immunogenicity of subunit trivalent influenza vaccine in children with acute lymphoblastic leukemia. Pediatr Infect Dis J 1998; 17:125-129.
18. Chisholm JC, Devine T, Charlett A, et al. Response to influenza immunisation during treatment for cancer. Arch Dis Child 2001; 84:496-500.
19. Shahgholi E, Ehsani MA, Salamati P, et al. Immunogenicity of trivalent influenza vaccine in children with acute lymphoblastic leukemia during maintenance therapy. Pediatr Blood Cancer 2010; 54:716-720.
20. CDC (Centers for Disease Control and Prevention). Licensure of a high-dose inactivated influenza vaccine for persons aged >or =65 years (Fluzone High-Dose) and guidance for use - United States, 2010. MMWR Morb Mortal Wkly Rep 59:485-486.
21. Fiore AE, Uyeki TM, Broder K, et al. MMWR Recomm Rep. 2010 Aug 6; 59(RR-8): 1-62. Erratum in: MMWR Recomm Rep. 2010 Aug 13; 59(31): 993. MMWR Recomm Rep. 2010 Sep 10; 59(35) 1147.
22. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). Centers for Disease Control and Prevention (CDC). MMWR Morb Mortal Wkly Rep 2001; 60:1128-1132.
23. Falsey AR, Treanor JJ, Tornieporth N, et al. Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. J Infect Dis 2009; 200:172-180.
24. Keitel WA, Atmar RL, Cate TR, et al. Safety of high doses of influenza vaccine and effect on antibody responses in elderly persons. Arch Intern Med 2006; 166:1121-1127.
25. Couch RB, Winokur P, Brady R, et al. Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects. Vaccine 2007; 25:7656-7663.
26. Allison JE, Glezen WP, Taber LH, et al. Reactogenicity and immunogenicity of bivalent influenza A and monovalent influenza B virus vaccines in high-risk children. J Infect Dis 1977; 136:S672-S676.
27. Borella L, Webster RG. The immunosuppressive effects of long-term combination chemotherapy in children with acute leukemia in remission. Cancer Res 1971; 31:420-426.
28. Brown AE, Steinherz PG, Miller DR, et al. Immunization against influenza in children with cancer: Results of a three-dose trial. J Infect Dis 1982; 145:126.
29. Feery BJ, Sullivan JR, Hurley TH, et al. Immunization with influenza vaccine in patients with haematological malignant disease. Med J Aust 1977; 1:292-294.
30. Gross PA, Lee H, Wolff JA, et al. Influenza immunization in immunosuppressed children. J Pediatr 1978; 92:30-35.
31. Lange B, Shapiro SA, Waldman MT, et al. Antibody responses to influenza immunization of children with acute lymphoblastic leukemia. J Infect Dis 1979; 140:402-406.
32. Smithson WA, Siem RA, Ritts RE Jr, et al. Response to influenza virus vaccine in children receiving chemotherapy for malignancy. J Pediatr 1978; 93:632-634.
33. Sumaya CV, Williams TE, Brunell PA. Bivalent influenza vaccine in children with cancer. J Infect Dis 1977; 136:S656-S660.